Nektar Therapeutics Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Nektar Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View analyst ratings for Nektar Therapeutics or view top-rated stocks.

Wall Street analysts have given Nektar Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nektar Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.04. The biopharmaceutical company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $26.15 million. Nektar Therapeutics had a negative net margin of 340.31% and a negative trailing twelve-month return on equity of 38.12%. The company's quarterly revenue was down 53.4% compared to the same quarter last year. During the same period last year, the business earned ($0.78) earnings per share.
View Nektar Therapeutics' earnings history.

Nektar Therapeutics' stock was trading at $16.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NKTR shares have increased by 6.9% and is now trading at $17.61.
View which stocks have been most impacted by COVID-19.

6 brokers have issued 1-year price objectives for Nektar Therapeutics' shares. Their forecasts range from $18.00 to $26.00. On average, they anticipate Nektar Therapeutics' share price to reach $23.00 in the next year. This suggests a possible upside of 30.6% from the stock's current price.
View analysts' price targets for Nektar Therapeutics or view top-rated stocks among Wall Street analysts.

46 employees have rated Nektar Therapeutics CEO Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among Nektar Therapeutics' employees.

Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of NKTR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (10.44%), Primecap Management Co. CA (9.96%), Maverick Capital Ltd. (3.21%), Bellevue Group AG (2.17%), Geode Capital Management LLC (1.28%) and Camber Capital Management LP (1.10%). Company insiders that own Nektar Therapeutics stock include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Mark Andrew Wilson, R Scott Greer, Robert Chess and Stephen K Doberstein.
View institutional ownership trends for Nektar Therapeutics.

NKTR stock was sold by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Millennium Management LLC, Goldman Sachs Group Inc., D. E. Shaw & Co. Inc., Camber Capital Management LP, Primecap Management Co. CA, Burleson & Company LLC, and Ergoteles LLC. Company insiders that have sold Nektar Therapeutics company stock in the last year include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jonathan Zalevsky, Mark Andrew Wilson, R Scott Greer, and Robert Chess.
View insider buying and selling activity for Nektar Therapeutics or view top insider-selling stocks.

NKTR stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Duquesne Family Office LLC, BlackRock Inc., Putnam Investments LLC, Hennion & Walsh Asset Management Inc., Blair William & Co. IL, Dimensional Fund Advisors LP, and State of Tennessee Treasury Department.
View insider buying and selling activity for Nektar Therapeutics or or view top insider-buying stocks.

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NKTR stock can currently be purchased for approximately $17.61.

Nektar Therapeutics has a market capitalization of $3.21 billion and generates $152.91 million in revenue each year. The biopharmaceutical company earns $-444,440,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

Nektar Therapeutics employs 718 workers across the globe.

Nektar Therapeutics was founded in 1990.

The official website for Nektar Therapeutics is www.nektar.com.

Nektar Therapeutics is headquartered at 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]